CommercialPrior AuthMedium impact
08.02.07d, Glofitamab-gxbm (Columvi)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 28, 2025
We identified it
Jun 19, 2026
Summary
Medical necessity criteria have been updated for Glofitamab-gxbm (Columvi), a pharmacy drug used in oncology/hematology treatment. This policy change affects coverage determination and prior authorization requirements for this medication effective July 28, 2025.
Action Required
By July 28, 2025: Oncology and hematology providers must review updated medical necessity criteria for Glofitamab-gxbm (Columvi) prescriptions. Update prior authorization procedures and documentation requirements in billing system. Ensure all future prescriptions meet the new medical necessity guidelines to avoid claim denials.